Document Detail

Angioplasty versus stenting for superficial femoral artery lesions.
MedLine Citation:
PMID:  19370653     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Lower limb peripheral arterial disease (PAD) is a common, important manifestation of systemic atherosclerosis. Stenoses or occlusions in the superficial femoral artery may result in intermittent claudication as an early consequence, which may be treated by balloon angioplasty with or without stenting.
OBJECTIVES: The objective was to determine the effect of percutaneous transluminal angioplasty (PTA) when compared with PTA with stenting for lesions of the superficial femoral artery, for people with intermittent claudication or critical limb ischaemia.
SEARCH STRATEGY: The Cochrane Peripheral Vascular Diseases (PVD) Group searched their trials register (last searched February 2009) and the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (2009, Issue 1) for publications describing randomised controlled trials (RCTs) of percutaneous angioplasty with or without stenting.
SELECTION CRITERIA: Randomised trials of angioplasty alone versus angioplasty with stenting for the treatment of superficial femoral artery stenoses.
DATA COLLECTION AND ANALYSIS: Two authors (CT, JC) independently selected suitable trials,assessed trial quality and extracted data. A third author (AS) ranked the concealment of allocation and checked the final manuscript. The fourth author (DM) cross checked all stages of the review process.
MAIN RESULTS: Eight trials with 968 participants were included. The average age was 67 and all trials included men and women. Participants were followed for up to two years.There was a small but statistically significant improvement in primary angiographic and duplex patency at six months in patients treated with PTA plus stent over lesions treated with PTA alone (three trials and four trials, respectively). However, primary angiographic patency was non-significant 12 months (five trials, P = 0.23) and 24 months (two trials, P = 0.45). A similar but lesser effect was seen for ankle brachial pressure index (ABPI), while a more pronounced improvement in treadmill walking distance in patients with PTA plus stent insertion was observed at six and 12 (P < 0.0001), but not 24 months (P = 0.81). Only one trial reported quality of life, which showed no significant difference between patients treated with PTA alone or PTA with stent insertion at any time interval. Antiplatelet therapy protocols and inclusion criteria between trials showed marked heterogenicity.
AUTHORS' CONCLUSIONS: There is limited benefit to stenting lesions of the superficial femoral artery in addition to angioplasty, however this cannot be recommended routinely based on the results of this analysis.
Christopher P Twine; James Coulston; Ahmed Shandall; Alexander D McLain
Related Documents :
15071433 - Arterial remodeling and hemodynamics in carotid stents: a prospective duplex ultrasound...
9822053 - Treatment of takayasu's aortitis with percutaneous transluminal angioplasty and wall st...
14745323 - Evidence-based compression: prevention of stasis and deep vein thrombosis.
Publication Detail:
Type:  Journal Article; Meta-Analysis; Review     Date:  2009-04-15
Journal Detail:
Title:  The Cochrane database of systematic reviews     Volume:  -     ISSN:  1469-493X     ISO Abbreviation:  Cochrane Database Syst Rev     Publication Date:  2009  
Date Detail:
Created Date:  2009-04-16     Completed Date:  2009-06-23     Revised Date:  2014-07-15    
Medline Journal Info:
Nlm Unique ID:  100909747     Medline TA:  Cochrane Database Syst Rev     Country:  England    
Other Details:
Languages:  eng     Pagination:  CD006767     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Balloon / methods*
Anticoagulants / therapeutic use
Combined Modality Therapy / methods
Femoral Artery*
Intermittent Claudication / therapy
Peripheral Vascular Diseases / therapy*
Randomized Controlled Trials as Topic
Grant Support
CZB/4/609//Chief Scientist Office
Reg. No./Substance:
Update In:
Cochrane Database Syst Rev. 2014;6:CD006767   [PMID:  24959692 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Sertindole versus other atypical antipsychotics for schizophrenia.
Next Document:  Early amniotomy and early oxytocin for prevention of, or therapy for, delay in first stage spontaneo...